{
    "clinical_study": {
        "@rank": "149645", 
        "arm_group": [
            {
                "arm_group_label": "Baricitinib (Healthy)", 
                "arm_group_type": "Experimental", 
                "description": "Group 1.  4 mg baricitinib administered once, orally, to participants with normal hepatic function."
            }, 
            {
                "arm_group_label": "Baricitinib (Moderate)", 
                "arm_group_type": "Experimental", 
                "description": "Group 2.  4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment."
            }, 
            {
                "arm_group_label": "Baricitinib (Mild)", 
                "arm_group_type": "Experimental", 
                "description": "Group 3.  4 mg baricitinib administered once, orally, to participants with mild hepatic impairment.   Enrollment is contingent on data from Groups 1 and 2."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to measure how much of the study drug called baricitinib\n      gets into the blood stream and how long it takes the body to get rid of it.  Healthy\n      participants and those with liver disease may enroll.  The study will last about 7 days for\n      each participant, not including screening."
        }, 
        "brief_title": "A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Liver Diseases", 
            "Hepatic Insufficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Hepatic Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria for ALL Participants:\n\n          -  Male participants agree to use 2 reliable methods of birth control with female\n             partners of child-bearing potential during the study and for at least 3 months\n             following the last dose of study drug\n\n          -  Women not of child-bearing potential due to surgical sterilization (at least 6 weeks\n             after surgical bilateral oophorectomy with or without hysterectomy or at least 6\n             weeks after confirmed tubal occlusion/tubal ligation) confirmed by medical history,\n             or menopause\n\n          -  Menopausal women with spontaneous amenorrhea for at least 12 months, not induced by a\n             medical condition and by medications and have a follicle-stimulating hormone (FSH)\n             level greater than 40 milli-international units per milliliter (mIU/mL) (unless the\n             participant is taking hormone replacement therapy [HRT])\n\n          -  Have a body mass index of 18.5 to 40.0 kilograms per square meter (kg/m^2) inclusive\n             at the time of screening\n\n        Additional Inclusion Criteria for Healthy Participants:\n\n          -  Are overtly healthy participants, have normal hepatic function and have stable\n             chronic medical conditions\n\n          -  Have clinical laboratory test results within normal reference range for the\n             population or investigator site, or results with acceptable deviations that are\n             judged to be not clinically significant by the investigator\n\n        Additional Inclusion Criteria for Hepatically Impaired Participants:\n\n          -  Participants with hepatic impairment classified as Child-Pugh score A or B (mild\n             [Group 3, if enrolled] or moderate [Group 2] impairment, respectively).  Must have a\n             diagnosis of chronic hepatic impairment (greater than 6 months), with no clinically\n             significant changes within 90 days prior to study drug administration (Day 1).\n             Participants may have mild stable baseline medical conditions for which neither the\n             condition nor treatments received would negatively impact the health of the\n             participant or study conduct\n\n          -  Clinical laboratory test results with deviations that are judged by the investigator\n             to be compatible with the hepatic impairment of the participant, or of no additional\n             clinical significance for this study\n\n        Exclusion Criteria for ALL Participants:\n\n          -  Have received, within the last 30 days, an investigational product as part of a\n             clinical trial, or are concurrently enrolled in any other type of medical research\n             judged not to be scientifically or medically compatible with this study\n\n          -  Persons who have previously completed or withdrawn from study investigating\n             baricitinib, and have previously received the investigational product\n\n          -  Women with a positive pregnancy test or who are lactating\n\n          -  Have a current or recent history (less than 30 days prior to screening and/or less\n             than 45 days prior to admission to the clinical research unit) of a clinically\n             significant bacterial, fungal, parasitic, viral (excluding rhinopharyngitis), or\n             mycobacterial infection\n\n          -  Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior\n             to the first dose\n\n          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human\n             HIV antibodies\n\n          -  Have been exposed to a live vaccine within 12 weeks prior to the first dose or\n             expected to need/receive a live vaccine (including herpes zoster vaccination) during\n             the course of the study\n\n        Additional Exclusion Criteria for Healthy Participants:\n\n          -  Show evidence of acute or chronic liver disease\n\n          -  Show evidence of hepatitis B and/or positive hepatitis B and/or positive hepatitis B\n             surface antigen\n\n          -  Show evidence of hepatitis C and/or positive hepatitis C antibody\n\n          -  Intend to use over-the-counter or prescription medication and/or herbal supplements\n             within 14 days prior to dosing and during the study\n\n        Additional Exclusion Criteria for Liver Impaired Participants:\n\n          -  Have creatinine clearance less than or equal to 50 milli-liter per minute (mL/min)\n             using the Cockcroft and Gault formula\n\n          -  Show evidence of spontaneous bacterial peritonitis within 6 month of dosing\n\n          -  Have had variceal bleeding within 3 months of check in\n\n          -  Show evidence of severe hyponatremia (sodium less than 120 millimolar per liter\n             (mmol/L)\n\n          -  Have severe encephalopathy(Grade 3 to 4)\n\n          -  Have moderate to severe ascites (moderately hepatically impaired participants only)\n\n          -  Show presence of a portal shunt\n\n          -  Have hemoglobin less than 9.0 grams per deciliter (g/dL)\n\n          -  Have serum bilirubin greater than 15 milligrams per deciliter (mg/dL)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870388", 
            "org_study_id": "14600", 
            "secondary_id": "I4V-MC-JAGC"
        }, 
        "intervention": {
            "arm_group_label": [
                "Baricitinib (Healthy)", 
                "Baricitinib (Moderate)", 
                "Baricitinib (Mild)"
            ], 
            "description": "Administered orally", 
            "intervention_name": "Baricitinib", 
            "intervention_type": "Drug", 
            "other_name": "LY3009104"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009104", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 48 hours post dose"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity [AUC(0-\u221e)] of LY3009104", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 48 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}